Furthermore, compound 45 was found to possess anti-diabetic and anti-obesity capacities through promoting glucose consumption and suppressing lipid accumulation, whereas compound 178 had a potent PTP1B inhibition capacity compared to suramin, suggesting its possible application in anti-diabetic and anti-sleeping sickness therapeutic agents. Here, PTPN1 is linked to obesity disorder.